Published in Cancer Weekly, August 22nd, 2006
"Genetic and molecular techniques have provided increasing insights into the biology of AML. These investigations showed that AML is not a homogeneous disease but a heterogeneous group of biologically different subentities," investigators in Germany reported.
"These subentities are currently primarily defined by cytogenetics and molecular markers. They differ substantially in response to therapy and long-term outcome and hence allow different risk groups of patients to be defined," explained W. Hiddemann and colleagues, University of Munich.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.